{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T09:56:58Z","timestamp":1761991018032,"version":"build-2065373602"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,7,15]],"date-time":"2019-07-15T00:00:00Z","timestamp":1563148800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100013993","name":"Theravance Biopharma US","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013993","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Global Antimicrobial Resistance"],"published-print":{"date-parts":[[2020,3]]},"DOI":"10.1016\/j.jgar.2019.07.007","type":"journal-article","created":{"date-parts":[[2019,7,17]],"date-time":"2019-07-17T12:05:42Z","timestamp":1563365142000},"page":"118-123","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Regional analysis of telavancin and comparator antimicrobial activity against multidrug-resistant Staphylococcus aureus collected in the USA 2014\u20132016"],"prefix":"10.1016","volume":"20","author":[{"given":"Leonard R.","family":"Duncan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caitlin J.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert K.","family":"Flamm","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rodrigo E.","family":"Mendes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"year":"2016","series-title":"Package insert","author":"VIBATIV Package Insert","key":"10.1016\/j.jgar.2019.07.007_bib0005"},{"issue":"1","key":"10.1016\/j.jgar.2019.07.007_bib0010","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.diagmicrobio.2017.05.012","article-title":"Evaluation of the bactericidal activity of telavancin against Staphylococcus aureus using revised testing guidelines","volume":"89","author":"Sweeney","year":"2017","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"Suppl. 2","key":"10.1016\/j.jgar.2019.07.007_bib0015","doi-asserted-by":"crossref","first-page":"S58","DOI":"10.1093\/cid\/civ534","article-title":"Telavancin: mechanisms of action, in vitro activity, and mechanisms of resistance","volume":"61","author":"Karlowsky","year":"2015","journal-title":"Clin Infect Dis"},{"year":"2015","series-title":"Product monograph PrVIBATIVTM televancin for injection","key":"10.1016\/j.jgar.2019.07.007_bib0020"},{"issue":"3","key":"10.1016\/j.jgar.2019.07.007_bib0025","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1128\/AAC.49.3.1127-1134.2005","article-title":"Telavancin, a multifunctional lipoglycopeptide, disrupts both cell wall synthesis and cell membrane integrity in methicillin-resistant Staphylococcus aureus","volume":"49","author":"Higgins","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"issue":"10","key":"10.1016\/j.jgar.2019.07.007_bib0030","doi-asserted-by":"crossref","first-page":"6170","DOI":"10.1128\/AAC.00471-15","article-title":"Telavancin for acute bacterial skin and skin structure infections, a post hoc analysis of the phase 3 ATLAS trials in light of the 2013 FDA guidance","volume":"59","author":"Pushkin","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"10.1016\/j.jgar.2019.07.007_bib0035","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1093\/jac\/dkt490","article-title":"Analysis of phase 3 telavancin nosocomial pneumonia data excluding patients with severe renal impairment and acute renal failure","volume":"69","author":"Torres","year":"2014","journal-title":"J Antimicrob Chemother"},{"issue":"4","key":"10.1016\/j.jgar.2019.07.007_bib0040","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1177\/1753465816651594","article-title":"Telavancin in the treatment of Staphylococcus aureus hospital-acquired and ventilator-associated pneumonia: clinical evidence and experience","volume":"10","author":"Liapikou","year":"2016","journal-title":"Ther Adv Respir Dis"},{"issue":"1","key":"10.1016\/j.jgar.2019.07.007_bib0045","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1093\/cid\/ciq031","article-title":"Telavancin versus vancomycin for hospital-acquired pneumonia due to Gram-positive pathogens","volume":"52","author":"Rubinstein","year":"2011","journal-title":"Clin Infect Dis"},{"issue":"9","key":"10.1016\/j.jgar.2019.07.007_bib0050","doi-asserted-by":"crossref","first-page":"5547","DOI":"10.1128\/AAC.03172-14","article-title":"Revised reference broth microdilution method for testing telavancin: effect on MIC results and correlation with other testing methodologies","volume":"58","author":"Farrell","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"10.1016\/j.jgar.2019.07.007_bib0055","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1128\/AAC.04052-14","article-title":"Baseline activity of telavancin against Gram-positive clinical isolates responsible for documented infections in U.S. hospitals (2011-2012) as determined by the revised susceptibility testing method","volume":"59","author":"Mendes","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"10.1016\/j.jgar.2019.07.007_bib0060","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.diagmicrobio.2014.12.011","article-title":"Update of the telavancin activity in vitro tested against a worldwide collection of Gram-positive clinical isolates (2013), when applying the revised susceptibility testing method","volume":"81","author":"Mendes","year":"2015","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.jgar.2019.07.007_bib0065","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.jgar.2017.03.018","article-title":"Telavancin activity in vitro tested against a worldwide collection of gram-positive clinical isolates (2014)","volume":"10","author":"Duncan","year":"2017","journal-title":"J Glob Antimicrob Resist"},{"issue":"2","key":"10.1016\/j.jgar.2019.07.007_bib0070","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1179\/1973947815Y.0000000050","article-title":"Telavancin activity tested against Gram-positive clinical isolates from European, Russian and Israeli hospitals (2011-2013) using a revised broth microdilution testing method: redefining the baseline activity of telavancin","volume":"28","author":"Mendes","year":"2016","journal-title":"J Chemother"},{"issue":"1","key":"10.1016\/j.jgar.2019.07.007_bib0075","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1093\/jac\/dkr437","article-title":"MRSA: the first half century","volume":"67","author":"Moellering","year":"2012","journal-title":"J Antimicrob Chemother"},{"issue":"2","key":"10.1016\/j.jgar.2019.07.007_bib0080","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1128\/CMR.05022-11","article-title":"Predictors of mortality in Staphylococcus aureus bacteremia","volume":"25","author":"van Hal","year":"2012","journal-title":"Clin Microbiol Rev"},{"issue":"3","key":"10.1016\/j.jgar.2019.07.007_bib0085","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1093\/cid\/ciq146","article-title":"Clinical practice guidelines by the infectious diseases society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children","volume":"52","author":"Liu","year":"2011","journal-title":"Clin Infect Dis"},{"issue":"6-7","key":"10.1016\/j.jgar.2019.07.007_bib0090","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.ijmm.2013.02.007","article-title":"Community-associated MRSA: what makes them special?","volume":"303","author":"Otto","year":"2013","journal-title":"Int J Med Microbiol"},{"issue":"2","key":"10.1016\/j.jgar.2019.07.007_bib0095","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.ijantimicag.2011.09.028","article-title":"New insights into meticillin-resistant Staphylococcus aureus (MRSA) pathogenesis, treatment and resistance","volume":"39","author":"Gould","year":"2012","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.jgar.2019.07.007_bib0100","doi-asserted-by":"crossref","first-page":"S20","DOI":"10.1093\/cid\/cit614","article-title":"Methicillin-resistant Staphylococcus aureus therapy: past, present, and future","volume":"58 Suppl 1","author":"Rodvold","year":"2014","journal-title":"Clin Infect Dis"},{"issue":"6","key":"10.1016\/j.jgar.2019.07.007_bib0105","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1093\/cid\/cir935","article-title":"The clinical significance of vancomycin minimum inhibitory concentration in Staphylococcus aureus infections: a systematic review and meta-analysis","volume":"54","author":"van Hal","year":"2012","journal-title":"Clin Infect Dis"},{"issue":"3","key":"10.1016\/j.jgar.2019.07.007_bib0110","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1128\/AAC.04616-14","article-title":"Telavancin in vitro activity against a collection of methicillin-resistant Staphylococcus aureus isolates, including resistant subsets, from the United States","volume":"59","author":"Mendes","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"10.1016\/j.jgar.2019.07.007_bib0115","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1089\/mdr.2017.0022","article-title":"In vitro activity of telavancin against clinically important Gram-positive pathogens from 69 U.S. medical centers (2015): Potency analysis by U.S. census divisions","volume":"23","author":"Pfaller","year":"2017","journal-title":"Microb Drug Resist"},{"year":"2018","series-title":"Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard: eleventh edition","author":"CLSI. M07Ed11","key":"10.1016\/j.jgar.2019.07.007_bib0120"},{"year":"2018","series-title":"Performance standards for antimicrobial susceptibility testing: 28th informational supplement","author":"CLSI. M100Ed28","key":"10.1016\/j.jgar.2019.07.007_bib0125"},{"year":"2018","series-title":"Breakpoint tables for interpretation of MICs and zone diameters. Version 8.0","author":"EUCAST","key":"10.1016\/j.jgar.2019.07.007_bib0130"},{"year":"2018","series-title":"R: a language and environment for statistical computing","author":"R Core Team","key":"10.1016\/j.jgar.2019.07.007_bib0135"},{"issue":"14","key":"10.1016\/j.jgar.2019.07.007_bib0140","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1001\/jama.2014.1666","article-title":"National burden of invasive methicillin-resistant Staphylococcus aureus infection","volume":"311","author":"Malani","year":"2014","journal-title":"JAMA"},{"issue":"4","key":"10.1016\/j.jgar.2019.07.007_bib0145","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1128\/AAC.02803-15","article-title":"Linezolid surveillance results for the United States (LEADER Surveillance Program 2014)","volume":"60","author":"Flamm","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"10.1016\/j.jgar.2019.07.007_bib0150","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1186\/s13054-017-1801-3","article-title":"Incidence, prevalence, and management of MRSA bacteremia across patient populations-a review of recent developments in MRSA management and treatment","volume":"21","author":"Hassoun","year":"2017","journal-title":"Crit Care"}],"container-title":["Journal of Global Antimicrobial Resistance"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213716519301730?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213716519301730?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T09:53:11Z","timestamp":1761990791000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213716519301730"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3]]},"references-count":30,"alternative-id":["S2213716519301730"],"URL":"https:\/\/doi.org\/10.1016\/j.jgar.2019.07.007","relation":{},"ISSN":["2213-7165"],"issn-type":[{"type":"print","value":"2213-7165"}],"subject":[],"published":{"date-parts":[[2020,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Regional analysis of telavancin and comparator antimicrobial activity against multidrug-resistant Staphylococcus aureus collected in the USA 2014\u20132016","name":"articletitle","label":"Article Title"},{"value":"Journal of Global Antimicrobial Resistance","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jgar.2019.07.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Author(s). Published by Elsevier Ltd on behalf of International Society for Antimicrobial Chemotherapy.","name":"copyright","label":"Copyright"}]}}